4.7 Article

Mast cell-T cell axis alters development of colitis-dependent and colitis-independent colorectal tumours: potential for therapeutically targeting via mast cell inhibition

Journal

JOURNAL FOR IMMUNOTHERAPY OF CANCER
Volume 10, Issue 10, Pages -

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/jitc-2022-004653

Keywords

CD8-Positive T-Lymphocytes; Immune Evation; Immunotherapy; Tumor Microenvironment; Tumor Escape

Funding

  1. Sao Paulo Research Foundation (FAPESP) [2014/06428-5, 2018/00583-0]
  2. Foundation for Support to Teaching, Research and Assistance of the Hospital das Clinicas of the Faculty of Medicine of Ribeirao Preto, University of Sao Paulo (FAEPA)

Ask authors/readers for more resources

This study investigated the activity of mast cells (MCs) throughout the development of colorectal cancer (CRC) and found that MCs have a dual role in CRC development. MC activity promotes engraftment of tumor cells while inhibiting the infiltration of CD8+ cells. These findings suggest the potential of MCs as druggable targets for the treatment of CRC.
Background Colorectal cancer (CRC) has a high mortality rate and can develop in either colitis-dependent (colitis-associated (CA)-CRC) or colitis-independent (sporadic (s)CRC) manner. There has been a significant debate about whether mast cells (MCs) promote or inhibit the development of CRC. Herein we investigated MC activity throughout the multistepped development of CRC in both human patients and animal models. Methods We analyzed human patient matched samples of healthy colon vs CRC tissue alongside conducting a The Cancer Genome Atlas-based immunogenomic analysis and multiple experiments employing genetically engineered mouse (GEM) models. Results Analyzing human CRC samples revealed that MCs can be active or inactive in this disease. An activated MC population decreased the number of tumor-residing CD8 T cells. In mice, MC deficiency decreased the development of CA-CRC lesions, while it increased the density of tumor-based CD8 infiltration. Furthermore, co-culture experiments revealed that tumor-primed MCs promote apoptosis in CRC cells. In MC-deficient mice, we found that MCs inhibited the development of sCRC lesions. Further exploration of this with several GEM models confirmed that different immune responses alter and are altered by MC activity, which directly alters colon tumorigenesis. Since rescuing MC activity with bone marrow transplantation in MC-deficient mice or pharmacologically inhibiting MC effects impacts the development of sCRC lesions, we explored its therapeutic potential against CRC. MC activity promoted CRC cell engraftment by inhibiting CD8+ cell infiltration in tumors, pharmacologically blocking it inhibits the ability of allograft tumors to develop. This therapeutic strategy potentiated the cytotoxic activity of fluorouracil chemotherapy. Conclusion Therefore, we suggest that MCs have a dual role throughout CRC development and are potential druggable targets against this disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available